FDA Signals Shift In Thinking On Biosimilar Trials

Agency Moves Towards Streamlined Filings With Advice To Xbrane And Formycon

 
• By Dave Wallace
  
Two recent examples have been seen of fresh thinking from the FDA (Shutterstock)

More from Biosimilars

More from Policy & Regulation